Stefania Cheli

List of Publications by Year
in descending order

34 papers	397 citations	932766 10 h-index	794141 19 g-index
34 all docs	34 docs citations	34 times ranked	752 citing authors

#	Article	IF	Citations
1	Fast clearance of anti-TNFÎ± agents unrelated to antidrug antibodies: a case report. European Journal of Clinical Pharmacology, 2022, 78, 891-893.	0.8	3
2	Therapeutic drug monitoring and pharmacogenetics of antipsychotics and antidepressants in real life settings: A 5-year single centre experience. World Journal of Biological Psychiatry, 2021, 22, 34-45.	1.3	9
3	Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients. Pharmacogenomics Journal, 2021, 21, 491-497.	0.9	2
4	ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment. Pharmacogenomics Journal, 2021, 21, 586-593.	0.9	8
5	In linezolid underexposure, pharmacogenetics matters: The role of CYP3A5. Biomedicine and Pharmacotherapy, 2021, 139, 111631.	2.5	8
6	Case of Suboptimal Linezolid Exposure: Is There a Role for Pharmacogenetics?. Therapeutic Drug Monitoring, 2020, 42, 347-348.	1.0	2
7	Neonatal Outcomes in Maternal Depression in Relation to Intrauterine Drug Exposure. Frontiers in Pediatrics, 2019, 7, 309.	0.9	16
8	Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?. Pharmacogenomics Journal, 2019, 19, 465-472.	0.9	16
9	ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary study. Cancer Chemotherapy and Pharmacology, 2019, 83, 803-808.	1.1	8
10	Pharmacogenetic variants in bipolar disorder with elevated treatment resistance and intolerance: Towards a personalized pattern of care. Bipolar Disorders, 2019, 21, 288-291.	1.1	4
11	Different effects of glucocorticoids on darunavir plasma concentrations. European Journal of Clinical Pharmacology, 2019, 75, 733-735.	0.8	3
12	Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. BMC Infectious Diseases, 2018, 18, 556.	1.3	14
13	Clinical and genetic determinants of nevirapine plasma trough concentration. SAGE Open Medicine, 2018, 6, 205031211878086.	0.7	11
14	Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. Pharmacogenomics Journal, 2017, 17, 331-336.	0.9	10
15	Pharmacokinetics and Pharmacogenetics of Selective Serotonin Reuptake Inhibitors During Pregnancy: An Observational Study. Therapeutic Drug Monitoring, 2017, 39, 197-201.	1.0	17
16	Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors. Drug Metabolism and Personalized Therapy, 2017, 32, 115-117.	0.3	0
17	HLA-B*57. Pharmacogenetics and Genomics, 2017, 27, 81-82.	0.7	0
18	Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common DPYD Polymorphisms. Chemotherapy, 2017, 62, 323-326.	0.8	1

#	Article	IF	Citations
19	The combination of pharmacogenetic and pharmacokinetic analyses to optimize clomipramine dosing in major depression: a case report. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 119-121.	0.7	0
20	Renal function in <scp>HIV</scp>/<scp>HBV</scp> coâ€infected and <scp>HBV</scp> monoâ€infected patients on a longâ€term treatment with tenofovir in real life setting. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 191-196.	0.9	8
21	Genetic Factors Associated with Platinum Toxicity: A Preliminary Study. Annals of Oncology, 2017, 28, vi95.	0.6	0
22	Pharmacogenetic approach to losartan in Marfan patients: a starting point to improve dosing regimen?. Drug Metabolism and Personalized Therapy, 2016, 31, 157-163.	0.3	5
23	The role of Toll-like receptor 4 polymorphisms in vaccine immune response. Pharmacogenomics Journal, 2016, 16, 96-101.	0.9	12
24	LightSNiP assay is a good strategy for pharmacogenetics test. Frontiers in Pharmacology, 2015, 6, 114.	1.6	5
25	SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir. Journal of Antimicrobial Chemotherapy, 2015, 70, 1155-1160.	1.3	9
26	Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase. International Journal of Molecular Sciences, 2015, 16, 8884-8895.	1.8	13
27	DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. British Journal of Clinical Pharmacology, 2015, 80, 581-588.	1.1	52
28	ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors. Pharmacology, 2015, 96, 163-166.	0.9	2
29	The first steps towards the era of personalised vaccinology: predicting adverse reactions. Pharmacogenomics Journal, 2015, 15, 284-287.	0.9	14
30	Predictive testing for DPD deficiency in a patient with familial history of fluoropyrimidine-associated toxicity. Personalized Medicine, 2014, 11, 259-262.	0.8	4
31	Levofloxacin-induced seizures in a patient without predisposing risk factors: the impact of pharmacogenetics. European Journal of Clinical Pharmacology, 2013, 69, 1611-1613.	0.8	17
32	ACE inhibitors and ribavirin-associated cough: a common undefined predisposing factor?. European Journal of Clinical Pharmacology, 2013, 69, 743-745.	0.8	4
33	Expression Profiling of FSHD-1 and FSHD-2 Cells during Myogenic Differentiation Evidences Common and Distinctive Gene Dysregulation Patterns. PLoS ONE, 2011, 6, e20966.	1.1	39
34	Remodeling of the chromatin structure of the facioscapulohumeral muscular dystrophy (FSHD) locus and upregulation of FSHD-related gene 1 (FRG1) expression during human myogenic differentiation. BMC Biology, 2009, 7, 41.	1.7	81